Journey Medical Corporation (DERM)

NOW APPROVED: EMROSI™ (Minocycline Hydrochloride) Extended-Release Capsules, 40mg

Learn More

Latest Financial Results

Nov 12, 2025 • 4:01 PM EST

Q3 2025 Quarterly Results

Quarter Ended Sep 30, 2025

Earnings Release

Audio

Earnings Webcast

10-Q

PDF HTML

XBRL

ZIP HTML

Latest News

Nov 12, 2025 • 4:01pm EST

Journey Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

Read Press Release

Nov 5, 2025 • 8:30am EST

Journey Medical Corporation to Announce Third Quarter 2025 Financial Results on November 12, 2025

Oct 24, 2025 • 8:30am EDT

Journey Medical Corporation Reports Combined Emrosi™ (DFD-29) Phase 3 Clinical Trial Efficacy Data Analysis Presented at the 2025 Fall Clinical Dermatology Conference

Oct 8, 2025 • 8:30am EDT

Journey Medical Corporation to Participate in October 2025 Investor Conferences

View All SEC Filings

Q3 2025

Quarter Ended Sep 30, 2025

Earnings Release

Audio

Earnings Webcast

10-Q

PDF HTML

XBRL

ZIP HTML

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2024

Contacts

Corporate

Journey Medical Corporation
9237 East Via De Ventura
Suite 105
Scottsdale, AZ 85258
T: 480-434-6670
contact@jmcderm.com

Investor Relations

Jaclyn Jaffe
T: 781-652-4500
ir@jmcderm.com

Transfer Agent

VStock Transfer
Allison Niccolls
allison@vstocktransfer.com